Genmab A/S (OTCMKTS:GNMSF – Get Free Report) gapped up before the market opened on Wednesday . The stock had previously closed at $285.00, but opened at $305.00. Genmab A/S shares last traded at $304.99, with a volume of 908 shares traded.
Genmab A/S Trading Up 4.6%
The stock’s 50 day moving average price is $296.19 and its two-hundred day moving average price is $244.11. The firm has a market capitalization of $20.09 billion, a price-to-earnings ratio of 15.26 and a beta of 0.93.
Genmab A/S (OTCMKTS:GNMSF – Get Free Report) last announced its quarterly earnings data on Thursday, November 6th. The company reported $6.46 EPS for the quarter, beating the consensus estimate of $4.86 by $1.60. Genmab A/S had a net margin of 37.53% and a return on equity of 21.03%. The firm had revenue of $1.02 billion during the quarter, compared to analysts’ expectations of $1 billion.
About Genmab A/S
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.
Recommended Stories
- Five stocks we like better than Genmab A/S
- Buy P&G Now, Before It Sets A New All-Time High
- Why Bulls Should Want a Bigger Drop in Palantir Stock
- What is a Special Dividend?
- Papa John’s $2.7 Billion Takeover Bid: A Price on Untapped Value
- Pets Are Big Business: 4 Big-Ticket Pet Stocks to Add to Your Portfolio
- Is Qualcomm Up 40% or Down 20%? 2 Contrarian Takes
Receive News & Ratings for Genmab A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genmab A/S and related companies with MarketBeat.com's FREE daily email newsletter.
